CRDF
Cardiff Oncology, Inc.
$1.54
-3.14%
$105.3M
No data for this timeframe.
Vol
Market Cap$105.3M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders50 funds
Inst. Value$21.9M
Inst. Activity4 buys / 4 sells
Reddit Sentiment64° Warm
SEC Reports7
Press Releases4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001213037·Prev Close $1.59
Recent Activity
Jun 11, 2026
SEC
Four major institutions reduced CRDF holdings in Q3 2025, with Morgan Stanley, BofA, Two Sigma, and Nuveen collectively
INST-CLUSTER — Impact 4/10
Jun 3, 2026
SEC
Cardiff Oncology released an investor presentation detailing interim Phase 2 CRDF-004 data for onvansertib in first-line
8-K — Impact 7/10
Jun 2, 2026
fda
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
<p align="center"><em>- The trial achieved its primary goal of selecting the efficacious and safe d
May 29, 2026
SEC
Cardiff Oncology disclosed that its licensor, Nerviano Medical Sciences (NMS), has terminated the key license agreement
8-K — Impact 8/10
Apr 27, 2026
Insider
Aggarwal Ajay was granted 400,000 shares
Chief Operating Officer
Apr 14, 2026
Insider
Smeal Tod was granted 300,000 shares
Chief Scientific Officer
Apr 6, 2026
Insider
Muntner Joshua B was granted 486,650 shares
Chief Financial Officer
Inst.
BLAIR WILLIAM & CO/IL — TRIM
922,407 shares ($1.5M)
Price Targets
$5.36
+247.9% upside
Strong Buy
Current $1.54
Low $2.00
Median $4.00
High $12.00
7 analysts
$2.00
$12.00
Analyst Ratings
3Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | Craig-Hallum | DOWNGRADE | Buy → Hold |
| Jun 1, 2026 | TD Cowen | DOWNGRADE | Buy → Hold |
| Jun 1, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Feb 25, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Jan 28, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.16 ▼ -33.3% | $-0.20 — $-0.11 | 24% YoY | 6 |
| Next Q | $-0.17 ▼ -27.5% | $-0.20 — $-0.13 | 1% YoY | 6 |
| Current FY | $-0.69 ▼ -32.6% | $-0.78 — $-0.56 | 0% YoY | 6 |
| Next FY | $-0.81 ▼ -16.0% | $-0.86 — $-0.69 | -18% YoY | 5 |
Latest Reports
BEARISH
INST-CLUSTER
4/10
Four major institutions reduced CRDF holdings in Q3 2025, with Morgan Stanley, BofA, Two Sigma, and Nuveen collectively
Jun 11, 2026
BULLISH
8-K
7/10
Cardiff Oncology released an investor presentation detailing interim Phase 2 CRDF-004 data for onvansertib in first-line
Jun 3, 2026
BULLISH
Press
8/10
Cardiff Oncology announced positive Phase 2 data for onvansertib in first-line RAS-mutated mCRC at ASCO 2026, showing a
Jun 2, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $6.4M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.6M | — |
| FRANKLIN RESOURCES INC | $2.0M | — |
| STATE STREET CORP | $1.9M | — |
| BLAIR WILLIAM & CO/IL | $1.5M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 27, 2026 | Aggarwal Ajay | A | $0.00 |
| Apr 14, 2026 | Smeal Tod | A | $0.00 |
| Apr 6, 2026 | Muntner Joshua | A | $0.00 |
| Apr 6, 2026 | Muntner Joshua | A | $0.00 |
| Mar 31, 2026 | Mohindru Mani | A | $0.00 |
Reddit Sentiment
64°
Warm
Bearish
Neutral
Bullish
50 institutional holders with $21.9M total value (13,517,311 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, FRANKLIN.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3,981,387 | $6.4M | 29.5% | ADD +35.2% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2,855,966 | $4.6M | 21.2% | — |
| 3 | FRANKLIN RESOURCES INC | 1,205,803 | $2.0M | 8.9% | — |
| 4 | STATE STREET CORP | 1,186,947 | $1.9M | 8.8% | — |
| 5 | BLAIR WILLIAM & CO/IL | 922,407 | $1.5M | 6.8% | TRIM -52.7% |
| 6 | VANGUARD FIDUCIARY TRUST CO | 446,225 | $722.9K | 3.3% | — |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 437,214 | $708.3K | 3.2% | — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 270,900 | $438.9K | 2.0% | — |
| 9 | CITADEL ADVISORS LLC | 229,000 | $371.0K | 1.7% | — |
| 10 | TWO SIGMA INVESTMENTS, LP | 206,990 | $335.3K | 1.5% | DOUBLED +255.4% |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 164,708 | $266.8K | 1.2% | ADD +67.2% |
| 12 | GOLDMAN SACHS GROUP INC | 135,598 | $219.7K | 1.0% | — |
| 13 | Nuveen, LLC | 130,346 | $211.2K | 1.0% | ADD +62.5% |
| 14 | CITADEL ADVISORS LLC | 125,566 | $203.4K | 0.9% | — |
| 15 | RENAISSANCE TECHNOLOGIES LLC | 101,253 | $164.0K | 0.7% | — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 92,359 | $149.6K | 0.7% | — |
| 17 | ALLIANCEBERNSTEIN L.P. | 48,730 | $136.9K | 0.6% | — |
| 18 | RHUMBLINE ADVISERS | 73,896 | $119.7K | 0.5% | ADD +34.2% |
| 19 | Assenagon Asset Management S.A. | 67,231 | $108.9K | 0.5% | — |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 61,300 | $99.3K | 0.5% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BLAIR WILLIAM & CO/IL | TRIM | 1,948,847 | 922,407 | -52.7% | $1.5M | 2026-Q1 |
| Nuveen, LLC | ADD | 80,220 | 130,346 | +62.5% | $211.2K | 2026-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 235,834 | 56,306 | -76.1% | $91.2K | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 55,710 | 36,650 | -34.2% | $59.4K | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 41,874 | 25,175 | -39.9% | $40.8K | 2026-Q1 |
| CWM, LLC | DOUBLED | 495 | 3,040 | +514.1% | $4.9K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 58 | 707 | +1119.0% | $1.1K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 31,330 | 52,316 | +67.0% | $85.00 | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 204,010 | 724,957 | +255.4% | $2.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 58,519 | 83,830 | +43.3% | $235.6K | 2025-Q4 |
| Nuveen, LLC | TRIM | 194,310 | 80,220 | -58.7% | $225.4K | 2025-Q4 |
| DEUTSCHE BANK AG\ | DOUBLED | 748 | 43,888 | +5767.4% | $123.3K | 2025-Q4 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 13,740 | 19,436 | +41.5% | $54.6K | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | NEAR_EXIT | 236 | 58 | -75.4% | $163.00 | 2025-Q4 |
| HRT FINANCIAL LP | DOUBLED | 14,335 | 29,408 | +105.1% | $82.00 | 2025-Q4 |
| MORGAN STANLEY | TRIM | 795,746 | 310,659 | -61.0% | $640.0K | 2025-Q3 |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | 32 | 208,700 | +652087.5% | $429.9K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 443,521 | 204,010 | -54.0% | $420.3K | 2025-Q3 |
| Nuveen, LLC | TRIM | 560,269 | 194,310 | -65.3% | $400.3K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 46,139 | 58,519 | +26.8% | $120.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 93,393 | 49,321 | -47.2% | $101.6K | 2025-Q3 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | TRIM | 21,956 | 13,740 | -37.4% | $28.3K | 2025-Q3 |
| VOYA INVESTMENT MANAGEMENT LLC | TRIM | 17,885 | 12,562 | -29.8% | $25.9K | 2025-Q3 |
| NISA INVESTMENT ADVISORS, LLC | NEAR_EXIT | 4,909 | 209 | -95.7% | $431.00 | 2025-Q3 |
| CWM, LLC | TRIM | 691 | 444 | -35.7% | $1.00 | 2025-Q3 |
4 unique insiders with 5 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 27, 2026 | Aggarwal Ajay | Chief Operating Officer | AWARD | 400,000 | — | — |
| Apr 14, 2026 | Smeal Tod | Chief Scientific Officer | AWARD | 300,000 | — | — |
| Apr 6, 2026 | Muntner Joshua B | Chief Financial Officer | AWARD | 486,650 | — | — |
| Apr 6, 2026 | Muntner Joshua B | Chief Financial Officer | AWARD | 486,650 | — | — |
| Mar 31, 2026 | Mohindru Mani | Chief Executive Officer | AWARD | 600,000 | — | — |
7 SEC filing reports analyzed. Sentiment: 4 bullish, 3 bearish, 0 mixed, 0 neutral. Avg impact: 6.7/10.
BEARISH
INST-CLUSTER
4/10
Four major institutions reduced CRDF holdings in Q3 2025, with Morgan Stanley, BofA, Two Sigma, and
Jun 11, 2026
BULLISH
8-K
7/10
Cardiff Oncology released an investor presentation detailing interim Phase 2 CRDF-004 data for onvan
Jun 3, 2026
BEARISH
8-K
8/10
Cardiff Oncology disclosed that its licensor, Nerviano Medical Sciences (NMS), has terminated the ke
May 29, 2026
BEARISH
8-K
5/10
Cardiff Oncology filed a lawsuit against Nerviano Medical Sciences (NMS) to preemptively challenge N
May 19, 2026
BULLISH
8-K
7/10
Cardiff Oncology reported Q1 2026 results with a net loss of $0.18 per share, slightly narrower than
May 14, 2026
BULLISH
8-K
8/10
Cardiff Oncology released positive Phase 2 data for its drug onvansertib in first-line RAS-mutant me
Feb 25, 2026
BULLISH
8-K, 8-K
8/10
Cardiff Oncology reported positive Phase 2 clinical trial results for its lead drug onvansertib in f
Feb 24, 2026
BULLISH
8/10
Cardiff Oncology announced positive Phase 2 data for onvansertib in first-line RAS-mutated mCRC at A
Jun 2, 2026
NEUTRAL
4/10
Cardiff Oncology announced it will present updated Phase 2 data for onvansertib in RAS-mutated mCRC
May 21, 2026
BULLISH
7/10
Cardiff Oncology presented preclinical data at AACR 2026 showing that its PLK1 inhibitor onvansertib
Apr 17, 2026
MIXED
5/10
Cardiff Oncology announced preclinical data showing its PLK1 inhibitor onvansertib enhances the anti
Mar 19, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 14 analysts: 3 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.36 mean target
+247.9% upside
Strong Buy (2.13)
$2.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $1.54 |
| Target Low | $2.00 |
| Target Mean | $5.36 |
| Target Median | $4.00 |
| Target High | $12.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (2.13) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.16 | $-0.20 | $-0.11 | 23.8% | -33.3% | 0↑ 5↓ | $0.0B | -48.1% | 6 |
| Next Q 2026-09-30 |
$-0.17 | $-0.20 | $-0.13 | 1.0% | -27.5% | 0↑ 5↓ | $0.0B | -44.0% | 6 |
| Current FY 2026-12-31 |
$-0.69 | $-0.78 | $-0.56 | 0.5% | -32.6% | 0↑ 5↓ | $0.0B | -61.3% | 6 |
| Next FY 2027-12-31 |
$-0.81 | $-0.86 | $-0.69 | -18.3% | -16.0% | 0↑ 4↓ | $0.0B | -17.5% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.160 | |
| 7d ago | $-0.160 | |
| 30d ago | $-0.120 | -0.040 |
| 60d ago | $-0.120 | -0.040 |
| 90d ago | $-0.120 | -0.040 |
4 analyst firms have rated this stock: 0 upgrades, 3 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | Craig-Hallum | DOWNGRADE | Buy | Hold |
| Jun 1, 2026 | TD Cowen | DOWNGRADE | Buy | Hold |
| Jun 1, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Feb 25, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Jan 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
64°
Warm
Bearish
Neutral
Bullish
3 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 19, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| May 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
A few small caps I’m watching into the session
▲ 1
💬 1
⚡ 0.5
Jun 2, 2026
fda
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
<p align="center"><em>- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regime
Jun 2, 2026
short_volume
Short Volume: CRDF — 57.4% short (0.7M / 1.2M)
Short: 707,323 | Exempt: 56,792 | TRF Vol: 1,232,540 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
other
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
<p align="justify">SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company levera
Jun 1, 2026
short_volume
Short Volume: CRDF — 56.1% short (1.9M / 3.4M)
Short: 1,898,463 | Exempt: 267,600 | TRF Vol: 3,381,978 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: CRDF — 63.0% short (0.4M / 0.6M)
Short: 388,225 | Exempt: 172 | TRF Vol: 616,180 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: CRDF — 61.3% short (0.4M / 0.7M)
Short: 442,188 | Exempt: 1,200 | TRF Vol: 720,799 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
May 21, 2026
fda
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30
May 18, 2026
short_volume
Short Volume: CRDF — 62.1% short (0.4M / 0.6M)
Short: 382,975 | Exempt: 9,775 | TRF Vol: 616,686 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
<p align="center"><em>Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phas
Apr 30, 2026
earnings_calendar
CRDF Q1 2026 Earnings After Market Close — 2026-04-30
Apr 28, 2026
other
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>SAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PL
Apr 21, 2026
routine
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
<p>SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhib
Apr 17, 2026
fda
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low
Apr 15, 2026
short_volume
Short Volume: CRDF — 55.1% short (0.3M / 0.5M)
Short: 291,264 | Exempt: 1 | TRF Vol: 528,326 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
leadership
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
<p align="center"><em>Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer</em><br><br><em>Appoints industry v